Only one study demonstrated that combined PD-L1 positivity on CTCs and PD-L1 positive staining on tumor tissue could be a biomarker for better response to ICIs in patients with advanced NSCLC, while another study showed no correlation with PFS [31,32]. The gene discussed is CD274; the disease is neoplasm.